Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced PCV13 Dosing Schedule in Infants
NCT03384589Phase 3Completed
- Sponsor
- University of British Columbia
- Start
- Aug 2018
- Primary completion
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Prevnar 13 in invasive pneumococcal disease (IPD) (2 arms), sponsored by University of British Columbia. Primary endpoint: Immunogenicity of PCV13 post-booster. Started Aug 2018; status: completed.
02
Drugs
Prevnar 13
03
Conditions
invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on NCT03384589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384589.